CytoSorbents Q2 2024 GAAP EPS $(0.08) Beats $(0.10) Estimate, Sales $9.895M Beat $9.678M Estimate
Portfolio Pulse from Benzinga Newsdesk
CytoSorbents (NASDAQ:CTSO) reported Q2 2024 GAAP EPS of $(0.08), beating the $(0.10) estimate. Sales were $9.895M, surpassing the $9.678M estimate and showing a 5.03% increase from the same period last year.
August 13, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytoSorbents reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.08) beating the $(0.10) estimate and sales of $9.895M surpassing the $9.678M estimate. Sales also increased by 5.03% year-over-year.
The better-than-expected earnings and sales figures are likely to positively impact CytoSorbents' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100